Literature DB >> 17675400

Does triple-negative phenotype accurately identify basal-like tumour? An immunohistochemical analysis based on 143 'triple-negative' breast cancers.

F-C Bidard, R Conforti, T Boulet, S Michiels, S Delaloge, F André.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17675400     DOI： 10.1093/annonc/mdm360

Source DB:  PubMed          Journal:  Ann Oncol        ISSN： 0923-7534            Impact factor:   32.976


× No keyword cloud information.
  30 in total

1.  PET/CT and breast cancer subtypes.

Authors:  Laura Gilardi; Marco Colleoni; Giovanni Paganelli
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-09       Impact factor: 9.236

2.  Characteristics of triple-negative breast cancer in patients with a BRCA1 mutation: results from a population-based study of young women.

Authors:  Eunjung Lee; Roberta McKean-Cowdin; Huiyan Ma; Darcy V Spicer; David Van Den Berg; Leslie Bernstein; Giske Ursin
Journal:  J Clin Oncol       Date:  2011-10-17       Impact factor: 44.544

3.  Diagnosis of Basal-Like Breast Cancer Using a FOXC1-Based Assay.

Authors:  Tor W Jensen; Tania Ray; Jinhua Wang; Xiaodong Li; Wesley Y Naritoku; Bingchen Han; Frank Bellafiore; Sanjay P Bagaria; Annie Qu; Xiaojiang Cui; Clive R Taylor; Partha S Ray
Journal:  J Natl Cancer Inst       Date:  2015-06-03       Impact factor: 13.506

4.  Multiple testing of treatment-effect-modifying biomarkers in a randomized clinical trial with a survival endpoint.

Authors:  Stefan Michiels; Richard F Potthoff; Stephen L George
Journal:  Stat Med       Date:  2011-02-23       Impact factor: 2.373

5.  Capecitabine maintenance therapy for XT chemotherapy-sensitive patients with metastatic triple-negative breast cancer.

Authors:  Xu Liang; Lijun Di; Guohong Song; Ying Yan; Chaoying Wang; Hanfang Jiang; Huiping Li
Journal:  Chin J Cancer Res       Date:  2014-10       Impact factor: 5.087

6.  CD147, MMP9 expression and clinical significance of basal-like breast cancer.

Authors:  Ying Liu; Tao Xin; Qiu-Ying Jiang; Da-Yong Huang; Wei-Xi Shen; Li Li; Yan-Ju Lv; Ying-Hua Jin; Xiao-Wei Song; Chong Teng
Journal:  Med Oncol       Date:  2013-01-06       Impact factor: 3.064

7.  Triple-Negative Breast Cancer: Clinical and Histological Correlations.

Authors:  Zeinab Elsawaf; Hans-Peter Sinn
Journal:  Breast Care (Basel)       Date:  2011-08-26       Impact factor: 2.860

8.  Body size and risk of luminal, HER2-overexpressing, and triple-negative breast cancer in postmenopausal women.

Authors:  Amanda I Phipps; Kathleen E Malone; Peggy L Porter; Janet R Daling; Christopher I Li
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2008-07-29       Impact factor: 4.254

9.  Combined targeting of mTOR and AKT is an effective strategy for basal-like breast cancer in patient-derived xenograft models.

Authors:  Siguang Xu; Shunqiang Li; Zhanfang Guo; Jingqin Luo; Matthew J Ellis; Cynthia X Ma
Journal:  Mol Cancer Ther       Date:  2013-05-20       Impact factor: 6.261

10.  Epidemiology of breast cancer subtypes in two prospective cohort studies of breast cancer survivors.

Authors:  Marilyn L Kwan; Lawrence H Kushi; Erin Weltzien; Benjamin Maring; Susan E Kutner; Regan S Fulton; Marion M Lee; Christine B Ambrosone; Bette J Caan
Journal:  Breast Cancer Res       Date:  2009-05-22       Impact factor: 6.466
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.